Clinical Trial Update: Immunomodulatory Effects of PCSK9 Inhibition

View source ↗

Summary

A clinical trial examining the immunomodulatory effects of PCSK9 inhibition for cardiovascular disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Atherosclerotic Cardiovascular Disease
• Carotid Artery Disease
• Cerebrovascular Disease
• Coronary Artery Disease
• Peripheral Artery Disease
• Stroke
• Transient Ischemic Attack

Drugs mentioned

• LEQVIO (inclisiran)
• Praluent (alirocumab)
• Repatha (Evolocumab)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Atherosclerotic Cardiovascular Disease, Cardiovascular Diseases | Status: WITHDRAWN